Siolta Therapeutics
Kevin is an experimental biologist with expertise in biochemistry, cell biology, and physiology. He has over 10 years of experience studying metabolic and inflammatory disease, with a focus on Type 2 Diabetes and aging. In his work, Kevin has developed both in vivo and in vitro models and published 28 peer-reviewed scientific papers. His postdoctoral work at McMaster University in Ontario, Canada focused on host-microbe interactions in regulating glucose homeostasis during the progression of insulin resistance. Kevin’s expertise supports Siolta’s ongoing development of therapeutics to address metabolic disease.
This person is not in any offices
Siolta Therapeutics
Siolta Therapeutics is an early stage, venture-backed biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases.